InvestorsHub Logo
Followers 253
Posts 17893
Boards Moderated 0
Alias Born 01/19/2006

Re: DewDiligence post# 743

Monday, 02/05/2018 10:00:52 AM

Monday, February 05, 2018 10:00:52 AM

Post# of 1162
We appreciate our portfolio gain in BMY this morning in the face of a general, continued market decline.

The pfs data is good for those patients that respond to the Opdivo/Yervoy combination therapy in the Checkmate-227 trial.

What % of patients in the trial DID respond? I saw no report on that % in the links provided...I may have missed some data. Is BMY still looking for that magic molecule to combine with Opdivo or Opdivo/Yervoy to increase RRRs[Relative Response Rates] or ORRs[Overall Response Rates] in the population of patients treated with those immunotherapy molecules beyond the <30% or so usually quoted? Or did that particular trial exclude those patients that had been previously determined would not respond?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News